Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Allergy Therapeutics ( (GB:AGY) ) has provided an announcement.
Allergy Therapeutics reported a strong first half to its 2026 financial year, with revenues rising 7% to £36.3 million despite the ongoing phase-out of older unregistered products in Germany under the TAV programme, underlining renewed growth in its registered portfolio in its largest market. The company secured German marketing authorisation for Grassmuno, the first new subcutaneous grass pollen immunotherapy launch in that market in two decades and the first such product approved under TAV, and has begun commercialisation from January 2026, positioning it to benefit as competing products that fail to meet regulatory standards are withdrawn. The group ended December with £10.1 million in cash after using £55 million of warrant proceeds from shareholder lenders to repay all outstanding debt to them, significantly strengthening its balance sheet while retaining access to up to £70 million in uncommitted facilities and continuing to evaluate a potential dual primary listing in Hong Kong, moves that collectively support its growth strategy and ongoing R&D programmes, including its peanut allergy vaccine and paediatric development of Grassmuno.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, which poses significant risks. Despite strong technical indicators suggesting bullish momentum, the overbought condition may lead to a correction. The negative P/E ratio and lack of dividend yield further detract from the stock’s attractiveness.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a UK-headquartered international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including aluminium-free allergy immunotherapies with potential disease-modifying effects. The group markets proprietary and third‑party products through subsidiaries and branches in nine major European countries and via distribution partners in a further four markets, targeting key segments of the allergy immunotherapy market.
Average Trading Volume: 417,497
Technical Sentiment Signal: Buy
Current Market Cap: £743.1M
Find detailed analytics on AGY stock on TipRanks’ Stock Analysis page.